BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Solmi M, Fornaro M, Ostinelli EG, Zangani C, Croatto G, Monaco F, Krinitski D, Fusar-Poli P, Correll CU. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatry 2020;19:214-32. [PMID: 32394557 DOI: 10.1002/wps.20765] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 15.5] [Reference Citation Analysis]
Number Citing Articles
1 Yi W, Sylvester E, Lian J, Deng C. Kidney plays an important role in ketogenesis induced by risperidone and voluntary exercise in juvenile female rats. Psychiatry Research 2021;305:114196. [DOI: 10.1016/j.psychres.2021.114196] [Reference Citation Analysis]
2 Fusar-Poli P, Correll CU, Arango C, Berk M, Patel V, Ioannidis JPA. Preventive psychiatry: a blueprint for improving the mental health of young people. World Psychiatry 2021;20:200-21. [PMID: 34002494 DOI: 10.1002/wps.20869] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 16.0] [Reference Citation Analysis]
3 Roessner V, Eichele H, Stern JS, Skov L, Rizzo R, Debes NM, Nagy P, Cavanna AE, Termine C, Ganos C, Münchau A, Szejko N, Cath D, Müller-Vahl KR, Verdellen C, Hartmann A, Rothenberger A, Hoekstra PJ, Plessen KJ. European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment. Eur Child Adolesc Psychiatry 2021. [PMID: 34757514 DOI: 10.1007/s00787-021-01899-z] [Reference Citation Analysis]
4 Taurines R, Fekete S, Preuss-Wiedenhoff A, Warnke A, Wewetzer C, Plener P, Burger R, Gerlach M, Romanos M, Egberts KM. Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone. J Neural Transm (Vienna) 2022. [PMID: 35303169 DOI: 10.1007/s00702-022-02485-6] [Reference Citation Analysis]
5 Correll CU, Cortese S, Croatto G, Monaco F, Krinitski D, Arrondo G, Ostinelli EG, Zangani C, Fornaro M, Estradé A, Fusar-Poli P, Carvalho AF, Solmi M. Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review. World Psychiatry 2021;20:244-75. [PMID: 34002501 DOI: 10.1002/wps.20881] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
6 Ford JH 2nd, Kaur A, Rao D, Gilson A, Bolt DM, Garneau HC, Saldana L, McGovern MP. Improving Medication Access within Integrated Treatment for Individuals with Co-Occurring Disorders in Substance Use Treatment Agencies. Implement Res Pract 2021;2. [PMID: 34988462 DOI: 10.1177/26334895211033659] [Reference Citation Analysis]
7 Suk J, Soltis-vaughan B, Mahato K, Hwang S. Practical and Ethical Issues in Pediatric Psychopharmacology: Introductory Considerations. Psychiatric Annals 2021;51:450-8. [DOI: 10.3928/00485713-20210913-01] [Reference Citation Analysis]
8 Miola A, Fornaro M, Sambataro F, Solmi M. Melatonin and melatonin-agonists for metabolic syndrome components in patients treated with antipsychotics: A systematic review and meta-analysis. Hum Psychopharmacol 2021;:e2821. [PMID: 34687076 DOI: 10.1002/hup.2821] [Reference Citation Analysis]
9 Solmi M, Bodini L, Cocozza S, Seeman MV, Vieta E, Dragioti E, Carvalho AF, Fusar-poli P. Aripiprazole monotherapy as transdiagnostic intervention for the treatment of mental disorders: An umbrella review according to TRANSD criteria. European Neuropsychopharmacology 2020;41:16-27. [DOI: 10.1016/j.euroneuro.2020.09.635] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
10 Henderson A, Kinnear D, Fleming M, Stanley B, Greenlaw N, Young-Southward G, Pell JP, Cooper SA. Antipsychotic and antidepressant prescribing for 704 297 children and young people with and without intellectual disabilities: record linkage study. Br J Psychiatry 2021;218:58-62. [PMID: 33541472 DOI: 10.1192/bjp.2020.232] [Reference Citation Analysis]
11 Bushnell GA, Crystal S, Olfson M. Trends in Antipsychotic Medication Use in Young Privately Insured Children. J Am Acad Child Adolesc Psychiatry 2021;60:877-86. [PMID: 33091567 DOI: 10.1016/j.jaac.2020.09.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
12 Pereira Ribeiro J, Arthur EJ, Gluud C, Simonsen E, Storebø OJ. Does Methylphenidate Work in Children and Adolescents with Attention Deficit Hyperactivity Disorder? Pediatr Rep 2021;13:434-43. [PMID: 34449694 DOI: 10.3390/pediatric13030050] [Reference Citation Analysis]
13 Rusz CM, Ősz BE, Jîtcă G, Miklos A, Bătrînu MG, Imre S. Off-Label Medication: From a Simple Concept to Complex Practical Aspects. Int J Environ Res Public Health 2021;18:10447. [PMID: 34639747 DOI: 10.3390/ijerph181910447] [Reference Citation Analysis]
14 Musselman M, Faden J, Citrome L. Asenapine: an atypical antipsychotic with atypical formulations. Ther Adv Psychopharmacol 2021;11:20451253211035269. [PMID: 34540197 DOI: 10.1177/20451253211035269] [Reference Citation Analysis]
15 Correll CU, Tocco M, Pikalov A, Hsu J, Goldman R. Long-term safety and effectiveness of open-label lurasidone in antipsychotic-Naïve versus previously treated adolescents with Schizophrenia: A post-hoc analysis. Schizophr Res 2022;240:205-13. [PMID: 35032906 DOI: 10.1016/j.schres.2021.12.046] [Reference Citation Analysis]
16 Salazar de Pablo G, Solmi M, Vaquerizo-Serrano J, Radua J, Passina A, Mosillo P, Correll CU, Borgwardt S, Galderisi S, Bechdolf A, Pfennig A, Bauer M, Kessing LV, van Amelsvoort T, Nieman DH, Domschke K, Krebs MO, Sand M, Vieta E, McGuire P, Arango C, Shin JI, Fusar-Poli P. Primary prevention of depression: An umbrella review of controlled interventions. J Affect Disord 2021;294:957-70. [PMID: 34375224 DOI: 10.1016/j.jad.2021.07.101] [Reference Citation Analysis]
17 Correll CU, Findling RL, Tocco M, Pikalov A, Deng L, Goldman R. Safety and effectiveness of lurasidone in adolescents with schizophrenia: results of a 2-year, open-label extension study. CNS Spectr . [DOI: 10.1017/s1092852920001893] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
18 Luciano M, Sampogna G, Amore M, Andriola I, Calcagno P, Carmassi C, Del Vecchio V, Dell'Osso L, Di Lorenzo G, Gelao B, Giallonardo V, Rossi A, Rossi R, Siracusano A, Fiorillo A; LIFESTYLE Working Group. How to improve the physical health of people with severe mental illness? A multicentric randomized controlled trial on the efficacy of a lifestyle group intervention. Eur Psychiatry 2021;64:e72. [PMID: 34812136 DOI: 10.1192/j.eurpsy.2021.2253] [Reference Citation Analysis]
19 Heindel JJ, Howard S, Agay-Shay K, Arrebola JP, Audouze K, Babin PJ, Barouki R, Bansal A, Blanc E, Cave MC, Chatterjee S, Chevalier N, Choudhury M, Collier D, Connolly L, Coumoul X, Garruti G, Gilbertson M, Hoepner LA, Holloway AC, Howell G 3rd, Kassotis C, Kay MK, Ji Kim M, Lagadic-Gossmann D, Langouet S, Legrand A, Li Z, Le Mentec H, Lind L, Monica Lind P, Lustig RH, Martin-Chouly C, Munic Kos V, Podechard N, Roepke TA, Sargis RM, Starling A, Tomlinson CR, Touma C, Vondracek J, Vom Saal F, Blumberg B. Obesity II: Establishing Causal Links Between Chemical Exposures and Obesity. Biochem Pharmacol 2022;:115015. [PMID: 35395240 DOI: 10.1016/j.bcp.2022.115015] [Reference Citation Analysis]
20 Luciano M, Sampogna G, Del Vecchio V, Giallonardo V, Palummo C, Andriola I, Amore M, Rossi R, Carmassi C, Siracusano A, Fiorillo A; LIFESTYLE Working Group. The impact of clinical and social factors on the physical health of people with severe mental illness: Results from an Italian multicentre study. Psychiatry Res 2021;303:114073. [PMID: 34198214 DOI: 10.1016/j.psychres.2021.114073] [Reference Citation Analysis]
21 Costamagna I, Calisti F, Cattaneo A, Hsu J, Tocco M, Pikalov A, Goldman R. Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: A pooled post hoc analysis of double-blind, placebo-controlled 6-week studies. Eur Psychiatry 2021;64:e35. [PMID: 33966678 DOI: 10.1192/j.eurpsy.2021.30] [Reference Citation Analysis]
22 Delbello MP, Kadakia A, Heller V, Singh R, Hagi K, Nosaka T, Loebel A. Systematic Review and Network Meta-analysis: Efficacy and Safety of Second-Generation Antipsychotics in Youths With Bipolar Depression. Journal of the American Academy of Child & Adolescent Psychiatry 2021. [DOI: 10.1016/j.jaac.2021.03.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Salazar de Pablo G, Guinart D, Cornblatt BA, Auther AM, Carrión RE, Carbon M, Jiménez-Fernández S, Vernal DL, Walitza S, Gerstenberg M, Saba R, Lo Cascio N, Brandizzi M, Arango C, Moreno C, Van Meter A, Fusar-Poli P, Correll CU. DSM-5 Attenuated Psychosis Syndrome in Adolescents Hospitalized With Non-psychotic Psychiatric Disorders. Front Psychiatry 2020;11:568982. [PMID: 33192693 DOI: 10.3389/fpsyt.2020.568982] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Henn L, Zanta NC, Girardi CEN, Suchecki D. Chronic Escitalopram Treatment Does Not Alter the Effects of Neonatal Stress on Hippocampal BDNF Levels, 5-HT1A Expression and Emotional Behaviour of Male and Female Adolescent Rats. Mol Neurobiol 2021;58:926-43. [PMID: 33063280 DOI: 10.1007/s12035-020-02164-1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Ford JH 2nd, Rao D, Gilson A, Kaur A, Chokron Garneau H, Saldana L, McGovern MP. Wait No Longer: Reducing Medication Wait-Times for Individuals with Co-Occurring Disorders. J Dual Diagn 2022;:1-10. [PMID: 35387577 DOI: 10.1080/15504263.2022.2052225] [Reference Citation Analysis]
26 Stutzman DL. Long-term use of antidepressants, mood stabilizers, and antipsychotics in pediatric patients with a focus on appropriate deprescribing. Ment Health Clin 2021;11:320-33. [PMID: 34824957 DOI: 10.9740/mhc.2021.11.320] [Reference Citation Analysis]
27 Siafis S, Çıray O, Wu H, Schneider-Thoma J, Bighelli I, Krause M, Rodolico A, Ceraso A, Deste G, Huhn M, Fraguas D, San José Cáceres A, Mavridis D, Charman T, Murphy DG, Parellada M, Arango C, Leucht S. Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis. Mol Autism 2022;13:10. [PMID: 35246237 DOI: 10.1186/s13229-022-00488-4] [Reference Citation Analysis]
28 Correll CU, Fusar-poli P, Leucht S, Karow A, Maric N, Moreno C, Nordentoft M, Raballo A. Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe. NDT 2022;Volume 18:201-19. [DOI: 10.2147/ndt.s345066] [Reference Citation Analysis]
29 Huang S, Hu S, Liu S, Tang B, Liu Y, Tang L, Lei Y, Zhong L, Yang S, He S. Lithium carbonate alleviates colon inflammation through modulating gut microbiota and Treg cells in a GPR43-dependent manner. Pharmacol Res 2021;175:105992. [PMID: 34801681 DOI: 10.1016/j.phrs.2021.105992] [Reference Citation Analysis]
30 Wolff KT, Baglivio MT, Intravia J. Adverse childhood experiences (ACEs), psychotropic medication prescription, and continued offending among youth with serious offending histories in juvenile justice residential placement. Journal of Criminal Justice 2022. [DOI: 10.1016/j.jcrimjus.2022.101922] [Reference Citation Analysis]
31 Zhang J, Cheng X, Zhang H, Xu P, Jin P, Ke X. Analysis of the status of drug treatment in 746 inpatients with early-onset schizophrenia in China: a retrospective study. BMC Psychiatry 2021;21:10. [PMID: 33413200 DOI: 10.1186/s12888-020-02962-w] [Reference Citation Analysis]
32 Egberts KM, Gerlach M, Correll CU, Plener PL, Malzahn U, Heuschmann P, Unterecker S, Scherf-Clavel M, Rock H, Antony G, Briegel W, Fleischhaker C, Häge A, Hellenschmidt T, Imgart H, Kaess M, Karwautz A, Kölch M, Reitzle K, Renner T, Reuter-Dang SY, Rexroth C, Schulte-Körne G, Theisen FM, Walitza S, Wewetzer C, Fekete S, Taurines R, Romanos M. Serious Adverse Drug Reactions in Children and Adolescents Treated On- and Off-Label with Antidepressants and Antipsychotics in Clinical Practice. Pharmacopsychiatry 2022. [PMID: 35130562 DOI: 10.1055/a-1716-1856] [Reference Citation Analysis]
33 Capuzzi E, Capellazzi M, Caldiroli A, Cova F, Auxilia AM, Rubelli P, Tagliabue I, Zanvit FG, Peschi G, Buoli M, Clerici M. Screening for ADHD Symptoms among Criminal Offenders: Exploring the Association with Clinical Features. Healthcare 2022;10:180. [DOI: 10.3390/healthcare10020180] [Reference Citation Analysis]
34 Cong Z, Li D, Lv X, Yang C, Zhang Q, Wu C, Wang Z, Zhu X. α2A-adrenoceptor deficiency attenuates lipopolysaccharide-induced lung injury by increasing norepinephrine levels and inhibiting alveolar macrophage activation in acute respiratory distress syndrome. Clin Sci (Lond) 2020;134:1957-71. [PMID: 32643759 DOI: 10.1042/CS20200586] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
35 Faraone SV, Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, Newcorn JH, Gignac M, Al Saud NM, Manor I, Rohde LA, Yang L, Cortese S, Almagor D, Stein MA, Albatti TH, Aljoudi HF, Alqahtani MMJ, Asherson P, Atwoli L, Bölte S, Buitelaar JK, Crunelle CL, Daley D, Dalsgaard S, Döpfner M, Espinet S, Fitzgerald M, Franke B, Gerlach M, Haavik J, Hartman CA, Hartung CM, Hinshaw SP, Hoekstra PJ, Hollis C, Kollins SH, Sandra Kooij JJ, Kuntsi J, Larsson H, Li T, Liu J, Merzon E, Mattingly G, Mattos P, McCarthy S, Mikami AY, Molina BSG, Nigg JT, Purper-Ouakil D, Omigbodun OO, Polanczyk GV, Pollak Y, Poulton AS, Rajkumar RP, Reding A, Reif A, Rubia K, Rucklidge J, Romanos M, Ramos-Quiroga JA, Schellekens A, Scheres A, Schoeman R, Schweitzer JB, Shah H, Solanto MV, Sonuga-Barke E, Soutullo C, Steinhausen HC, Swanson JM, Thapar A, Tripp G, van de Glind G, Brink WVD, Van der Oord S, Venter A, Vitiello B, Walitza S, Wang Y. The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neurosci Biobehav Rev 2021;128:789-818. [PMID: 33549739 DOI: 10.1016/j.neubiorev.2021.01.022] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
36 Fiorillo A, Sartorius N. Mortality gap and physical comorbidity of people with severe mental disorders: the public health scandal. Ann Gen Psychiatry 2021;20:52. [PMID: 34903254 DOI: 10.1186/s12991-021-00374-y] [Reference Citation Analysis]
37 Egberts K, Fekete S, Häge A, Hiemke C, Scherf-Clavel M, Taurines R, Unterecker S, Gerlach M, Romanos M. [Therapeutic drug monitoring to optimize psychopharmacotherapy in children and adolescents - Update and guidelines for practice]. Z Kinder Jugendpsychiatr Psychother 2021;50:133-52. [PMID: 35274573 DOI: 10.1024/1422-4917/a000845] [Reference Citation Analysis]
38 Yin Y, Qian S, Chen Y, Sun Y, Li Y, Yu Y, Li J, Wu Z, Yu X, Ge R, Han J, Sun D, Wu H, Liu L, Xue W, Wang W. Latent Sex Differences in CaMKII-nNOS Signaling That Underlie Antidepressant-Like Effects of Yueju-Ganmaidazao Decoction in the Hippocampus. Front Behav Neurosci 2021;15:640258. [PMID: 34295228 DOI: 10.3389/fnbeh.2021.640258] [Reference Citation Analysis]
39 Mcwilliams S, Zhou T, Stockler S, Elbe D, Ipsiroglu OS. Sleep as an outcome measure in ADHD randomized controlled trials: a scoping review. Sleep Medicine Reviews 2022. [DOI: 10.1016/j.smrv.2022.101613] [Reference Citation Analysis]
40 Morgan AJ, Ross AM, Yap MBH, Reavley NJ, Parker A, Simmons MB, Scanlan F, Jorm AF. What works for mental health problems in youth? Survey of real-world experiences of treatments and side effects. Early Interv Psychiatry 2021;15:1502-12. [PMID: 33260268 DOI: 10.1111/eip.13087] [Reference Citation Analysis]
41 Fornaro M. There are no "side" effects, just "core" effects of antipsychotic pharmacotherapy. Acta Psychiatr Scand 2021;143:99-100. [PMID: 33452692 DOI: 10.1111/acps.13271] [Reference Citation Analysis]
42 Maruf AA, Stein K, Arnold PD, Aitchison KJ, Müller DJ, Bousman C. CYP2D6 and Antipsychotic Treatment Outcomes in Children and Youth: A Systematic Review. J Child Adolesc Psychopharmacol 2021;31:33-45. [PMID: 33074724 DOI: 10.1089/cap.2020.0093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
43 Menard ML, Ilies D, Abadie P, Jean-Baptiste T, Choquette R, Huet AS, Ben Amor L. Monitoring of metabolic adverse events of second-generation antipsychotics in a naive paediatric population followed in mental health outpatient and inpatient clinical settings: MEMAS prospective study protocol. BMJ Open 2021;11:e040764. [PMID: 33455928 DOI: 10.1136/bmjopen-2020-040764] [Reference Citation Analysis]
44 Methiwala HN, Vaidya B, Addanki VK, Bishnoi M, Sharma SS, Kondepudi KK. Gut microbiota in mental health and depression: role of pre/pro/synbiotics in their modulation. Food Funct 2021;12:4284-314. [PMID: 33955443 DOI: 10.1039/d0fo02855j] [Reference Citation Analysis]
45 Pinhas-Hamiel O, Bardugo A, Reichman B, Derazne E, Landau Z, Tokatly Latzer I, Lerner-Geva L, Rotschield J, Tzur D, Ben-Zvi D, Afek A, Twig G. Attention-Deficit Hyperactivity Disorder and Obesity - A National Study of 1.1 Million Israeli Adolescents. J Clin Endocrinol Metab 2021:dgab846. [PMID: 34850003 DOI: 10.1210/clinem/dgab846] [Reference Citation Analysis]